Advertisement

Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon

Published:September 08, 2022DOI:https://doi.org/10.1016/j.msard.2022.104169

      Highlights

      • Multiple sclerosis (MS) is associated with high societal and economic burden in Lebanon.
      • Cladribine tablets are a budget saving treatment option for HDA-RMS in Lebanon.
      • Cladribine tablets are the cost-effective treatment option for HDA-RMS in Lebanon.

      Abstract

      Background

      Cladribine tablets are a newly launched short course oral treatment approved for high disease activity (HDA) relapsing multiple sclerosis (RMS). The current analysis assessed the cost-utility and budgetary impact of introducing cladribine tablets in HDA-RMS patients compared with other HDA-RMS therapies in Lebanon.

      Methods

      The global cost-utility and budget impact models were adapted from Lebanese National Social Security Fund (NSSF) perspective. The data for the models’ adaptation were retrieved from the literature and validated by Lebanese experts. The comparators considered in the cost-utility model were alemtuzumab, fingolimod, and natalizumab while budget impact analysis additionally considered dimethyl fumarate. A sensitivity analysis was also performed to assess the uncertainty in the analysis.

      Results

      The cost-utility results showed that cladribine tablets are an economically dominant therapeutic strategy (i.e., less costly and better quality-adjusted life year [QALY]) compared to all comparators. The cost saving was driven by drug acquisition, administration, and monitoring costs; while incremental QALY gain was driven by differences in delayed Expanded Disability Status Scale progression. Sensitivity analysis showed that cladribine tablets have a high probability (99.3–100%) of being dominant at a threshold of 22,000 United States Dollars (approximately three times of gross domestic product) per QALY gained against different comparators. The budget impact analysis showed that the introduction of cladribine tablets would result in 5.0% to 21.5% savings in the overall budget over a period of five years.

      Conclusions

      Cladribine tablets are a cost-effective and a budget-saving treatment option for the treatment of HDA-RMS patients in Lebanon from the NSSF perspective.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Acaster S.
        • Perard R.
        • Chauhan D.
        • Lloyd A.J.
        A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis.
        BMC Health Serv. Res. 2013; 13: 1-8
        • Berardi A.
        • Siddiqui M.K.
        • Treharne C.
        • Harty G.
        • Wong S.L.
        Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatmen.
        Curr. Med. Res. Opin. 2019; 35: 1371-1378
        • Giovannoni G.
        • et al.
        A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
        N. Engl. J. Med. 2010; 362 (Feb.): 416-426
        • Giovannoni G.
        Cladribine to treat relapsing forms of multiple sclerosis.
        Neurotherapeutics. 2017; 14: 874-887
        • Giovannoni G.
        • et al.
        Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study.
        Mult. Scler. J. 2018; 24: 1594-1604
        • Hawton A.
        • Green C.
        Health utilities for multiple sclerosis.
        Value Health. 2016; 19: 460-468
        • Hawton A.J.
        • Green C.
        Multiple sclerosis: relapses, resource use, and costs.
        Eur. J. Health Econ. 2016; 17: 875-884
        • Hettle R.
        • Harty G.
        • Wong S.L.
        Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
        J. Med. Econ. 2018; 21: 676-686
        • Heydarpour P.
        • Khoshkish S.
        • Abtahi S.
        • Moradi-Lakeh M.
        • Sahraian M.A.
        Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis.
        Neuroepidemiology. 2015; 44: 232-244
        • Karampampa K.
        • Gustavsson A.
        • Miltenburger C.
        • Eckert B.
        Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries.
        Mult. Scler. J. 2012; 18 (_supplJun): 7-15
        • Kurtzke J.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33 (Nov): 1444-1452
        • Leist T.P.
        • et al.
        Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
        Lancet Neurol. 2014; 13 (Mar.): 257-267
        • Matza L.S.
        • et al.
        Health state utilities associated with attributes of treatments for hepatitis C.
        Eur. J. Health Econ. 2015; 16: 1005-1018
        • Montalban X.
        • et al.
        Cladribine tablets added to IFN-β in active relapsing MS.
        Neurol. Neuroimmunol. Neuroinflamm. 2018; 5 (Sep.): e477
      1. European Medicines Agency. Mavenclad: EPAR - Summary for the Public. 2017. Available from: https://www.ema.europa.eu/en/documents/overview/mavenclad-epar-summary-public_en.pdf.

      2. Multiple Sclerosis Trust. How common is multiple sclerosis?. 2021. Available from: https://mstrust.org.uk/a-z/how-common-multiple-sclerosis#targetText=Multiple sclerosis in the UK.

      3. National Institute for Health and Care Excellence (NICE). Cladribine for treating relapsing-remitting multiple sclerosis - Technology appraisal guidance [TA616]. 2019. Available from: https://www.nice.org.uk/guidance/ta616.

        • Orme M.
        • Kerrigan J.
        • Tyas D.
        • Russell N.
        • Nixon R.
        The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK.
        Value Health. 2007; 10: 54-60
        • Osenenko K.
        • Kherraf S.
        • Samy I.
        • Sambrook R.
        • Hersi A.
        Cost-effectiveness of apixaban for the treatment of atrial fibrillation patients in the Kingdom of Saudi Arabia.
        Value Health. 2016; 19: A652
        • Palace J.
        • et al.
        UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
        BMJ Open. 2014; 4: 1-10
        • Palace J.
        • et al.
        Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK multiple sclerosis risk sharing scheme at 6 years: a clinical cohort study with natural history comparator.
        Lancet Neurol. 2015; 14: 497-505
        • Pardo G.
        • Jones D.E.
        The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
        J. Neurol. 2017; 264: 2351-2374
        • Scolding N.
        • et al.
        Association of British neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
        Pract. Neurol. 2015; 15: 273-279
        • Shatila A.R.
        • et al.
        LSN MS guidelines for the management of multiple sclerosis.
        Rev. Neurol. 2013; 169 (Paris)Dec: 950-955
        • Siddiqui M.K.
        • Khurana I.S.
        • Budhia S.
        • Hettle R.
        • Harty G.
        • Wong S.L.
        Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis.
        Curr. Med. Res. Opin. 2018; 34: 1361-1371
        • Tappenden P.
        • et al.
        Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population.
        Value Health. 2009; 12: 657-665
      4. Olek MJ, Mowry E. Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults. 2022. Available from: https://www.uptodate.com/contents/initial-disease-modifying-therapy-for-relapsing-remitting-multiple-sclerosis-in-adults?search=initial-disease-modifying-therapy-for-relapsing-remitting-multiple-sclerosis-in-adults.&source=search_result&selectedTitle=1∼150&usage_type=default&display_rank=1.

        • Tappenden P
        • Chilcott J
        • O’Hagan T
        • Mccabe C
        • Cooper N
        • Abrams K
        • et al.
        Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis.
        Final Report to the National Institute for Clinical Excellence. 2001;
        • Torkildsen O.
        • Myhr K.M.
        • Bø L.
        Disease-modifying treatments for multiple sclerosis - a review of approved medications.
        Eur. J. Neurol. 2016; 23: 18-27
        • Trogdon J.G.
        • Ekwueme D.U.
        • Chamiec-Case L.
        • Guy G.P.
        Breast cancer in young women: health state utility impacts by race/ethnicity.
        Am. J. Prev. Med. 2016; 50: 262-269
        • Yamout B.
        • Barada W.
        • Tohme R.A.
        • Mehio-Sibai A.
        • Khalifeh R.
        • El-Hajj T.
        Clinical characteristics of multiple sclerosis in Lebanon.
        J. Neurol. Sci. 2008; 270: 88-93
      5. World Health Organization (WHO). Global Health Observatory data repository. Life tables by country - Lebanon. 2018. Available from: https://apps.who.int/gho/data/view.main.60910?lang=en.